Given as monotherapy or in combination with trametinib (MEK inhibitor)
- Mechanism of Action
- Normally, activation of RAS pathway via receptor tyrosine kinases (RTKs) results in activation of BRAF which then activates MEK, and in turn, ERK.
The RAS / RAF / MEK / ERK pathway stimulates cell proliferation and survival.
In melanoma with BRAF mutations, the mutant BRAF (most commonly V600E) is constitutionally active.
BRAF inhibitors bind to mutant BRAF V600 and, in turn, inhibit cellular proliferation in cells with BRAF mutations.
- Unresectable stage III or metastatic (stage IV) melanoma with BRAF (V600) mutation
- Adjuvant treatment of melanoma with BRAF (V600) mutation and lymph node involvement (dabrafenib + trametinib)
- Adverse Effects
- Papillomas / squamous cell carcinomas
- Nausea / vomiting / diarrhoea
- Arthralgia / myalgia
Want more info like this?
- Your electronic clinical medicine handbook
- Guides to help pass your exams
- Tools every medical student needs
- Quick diagrams to have the answers, fast
- Quizzes to test your knowledge